Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD)
Autistic spectrum disease (ASD) is an increasingly common diagnosis nowadays with a prevalence of 1–2% in most countries. Its complex causality—a combination of genetic, immune, metabolic, and environmental factors—is translated into pleiomorphic developmental disorders of various severity, which ha...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/8/1736 |
| _version_ | 1797584106041638912 |
|---|---|
| author | Felician Stancioiu Raluca Bogdan Radu Dumitrescu |
| author_facet | Felician Stancioiu Raluca Bogdan Radu Dumitrescu |
| author_sort | Felician Stancioiu |
| collection | DOAJ |
| description | Autistic spectrum disease (ASD) is an increasingly common diagnosis nowadays with a prevalence of 1–2% in most countries. Its complex causality—a combination of genetic, immune, metabolic, and environmental factors—is translated into pleiomorphic developmental disorders of various severity, which have two main aspects in common: repetitive, restrictive behaviors and difficulties in social interaction varying from awkward habits and verbalization to a complete lack of interest for the outside world. The wide variety of ASD causes also makes it very difficult to find a common denominator—a disease biomarker and medication—and currently, there is no commonly used diagnostic and therapeutic strategy besides clinical evaluation and psychotherapy. In the CORDUS clinical study, we have administered autologous cord blood to ASD kids who had little or no improvement after other treatments and searched for a biomarker which could help predict the degree of improvement in each patient. We have found that the neuron-specific enolase (NSE) was elevated above the normal clinical range (less than 16.3 ng/mL) in the vast majority of ASD kids tested in our study (40 of 41, or 97.5%). This finding opens up a new direction for diagnostic confirmation, dynamic evaluation, and therapeutic intervention for ASD kids. |
| first_indexed | 2024-03-10T23:47:33Z |
| format | Article |
| id | doaj.art-6f38ed6fd15740a3b32039c9e8bb1e79 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T23:47:33Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-6f38ed6fd15740a3b32039c9e8bb1e792023-11-19T01:54:53ZengMDPI AGLife2075-17292023-08-01138173610.3390/life13081736Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD)Felician Stancioiu0Raluca Bogdan1Radu Dumitrescu2Fundatia Bio-Forum, 040245 Bucharest, RomaniaMedicover Hospital Bucharest, 013982 Bucharest, RomaniaMedicover Hospital Bucharest, 013982 Bucharest, RomaniaAutistic spectrum disease (ASD) is an increasingly common diagnosis nowadays with a prevalence of 1–2% in most countries. Its complex causality—a combination of genetic, immune, metabolic, and environmental factors—is translated into pleiomorphic developmental disorders of various severity, which have two main aspects in common: repetitive, restrictive behaviors and difficulties in social interaction varying from awkward habits and verbalization to a complete lack of interest for the outside world. The wide variety of ASD causes also makes it very difficult to find a common denominator—a disease biomarker and medication—and currently, there is no commonly used diagnostic and therapeutic strategy besides clinical evaluation and psychotherapy. In the CORDUS clinical study, we have administered autologous cord blood to ASD kids who had little or no improvement after other treatments and searched for a biomarker which could help predict the degree of improvement in each patient. We have found that the neuron-specific enolase (NSE) was elevated above the normal clinical range (less than 16.3 ng/mL) in the vast majority of ASD kids tested in our study (40 of 41, or 97.5%). This finding opens up a new direction for diagnostic confirmation, dynamic evaluation, and therapeutic intervention for ASD kids.https://www.mdpi.com/2075-1729/13/8/1736autistic spectrum disease (ASD)autismneuron-specific enolase (NSE)autism biomarkerneuroinflammationneuronal apoptosis |
| spellingShingle | Felician Stancioiu Raluca Bogdan Radu Dumitrescu Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD) Life autistic spectrum disease (ASD) autism neuron-specific enolase (NSE) autism biomarker neuroinflammation neuronal apoptosis |
| title | Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD) |
| title_full | Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD) |
| title_fullStr | Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD) |
| title_full_unstemmed | Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD) |
| title_short | Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD) |
| title_sort | neuron specific enolase nse as a biomarker for autistic spectrum disease asd |
| topic | autistic spectrum disease (ASD) autism neuron-specific enolase (NSE) autism biomarker neuroinflammation neuronal apoptosis |
| url | https://www.mdpi.com/2075-1729/13/8/1736 |
| work_keys_str_mv | AT felicianstancioiu neuronspecificenolasenseasabiomarkerforautisticspectrumdiseaseasd AT ralucabogdan neuronspecificenolasenseasabiomarkerforautisticspectrumdiseaseasd AT radudumitrescu neuronspecificenolasenseasabiomarkerforautisticspectrumdiseaseasd |